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A B S T R A C T
Every day approximately six thousand people die of Tuberculosis (TB). Its causative agent, Mycobacterium tu-
berculosis (Mtb), is an ancient pathogen that through its evolution developed complex mechanisms to evade
immune surveillance and acquire the ability to establish persistent infection in its hosts. Currently, it is estimated
that one-fourth of the human population is latently infected with Mtb and among those infected 3–10% are at
risk of developing active TB disease during their lifetime. The currently available diagnostics are not able to
detect this risk group for prophylactic treatment to prevent transmission. Anti-TB drugs are available but only as
long regimens with considerable side effects, which could both be reduced if adequate tests were available to
monitor the response of TB to treatment. New vaccines are also urgently needed to substitute or boost Bacille
Calmette-Guérin (BCG), the only approved TB vaccine: although BCG prevents disseminated TB in infants, it fails
to impact the incidence of pulmonary TB in adults, and therefore has little effect on TB transmission. To achieve
TB eradication, the discovery of Mtb antigens that effectively correlate with the human response to infection,
with the curative host response following TB treatment, and with natural as well as vaccine induced protection
will be critical.
Over the last decade, many new Mtb antigens have been found and proposed as TB biomarkers and vaccine
candidates, but only a very small number of these is being used in commercial diagnostic tests or is being
assessed as candidate TB vaccine antigens in human clinical trials, aiming to prevent infection, disease or disease
recurrence following treatment. Most of these antigens were discovered decades ago, before the complete Mtb
genome sequence became available, and thus did not harness the latest insights from post-genomic antigen
discovery strategies and genome wide approaches. These have, for example, revealed critical phase variation in
Mtb replication and accompanying gene –and therefore antigen– expression patterns. In this review, we present a
brief overview of past methodologies, and subsequently focus on the most important recent Mtb antigen dis-
covery studies which have mined the Mtb antigenome through “unbiased” genome wide approaches. We com-
pare the results for these approaches -as far as we know for the first time-, highlight Mtb antigens that have been
identified independently by different strategies and present a comprehensive overview of the Mtb antigens thus
discovered.
1. Introduction: classical antigens, latency antigens, rpfs, and
vaccine potential
Tuberculosis (TB)is an ancient infectious disease [1] that has killed
approximately one billion people during the last two centuries [2].
Every year more than 10 million people develop active TB disease, and
almost 2 million die from TB, also known as the white plague. Despite
the fact that global TB control efforts avert millions of cases and hun-
dred thousands of deaths every year, TB remains the leading cause of
mortality from a single infectious agent worldwide [3]. The protective
efficacy of Bacille Calmette-Guérin (BCG), the only licensed TB vaccine,
is variable and inconsistent, ranging from 0 to 80%, and even though it
is effective in reducing the incidence of disseminated TB in children, it
is clearly insufficient in preventing the onset of pulmonary TB in ado-
lescents and adults [4]. The current diagnostics for Mycobacterium tu-
berculosis (Mtb) infection, the century old tuberculin skin test (TST) and
the more recent interferon-gamma release assays (IGRAs), are indirect
measures of infection as these tests determine previous host sensitiza-
tion to Mtb antigens by detecting memory T cell responses. Moreover
their diagnostic performance in HIV/TB-co-infected patients is poor
when CD4+ T cell counts are diminished. These tests also cannot dis-
tinguish between active TB and latent TB infection (LTBI), and have
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virtually no predictive value in estimating the risk of progression from
latent to active state of disease, which typically happens in 3–10% of
those infected [5]. In the past decades, development of better diag-
nostics and vaccines has been a key goal in TB research, yet thwarted by
the incomplete understanding of the complex and heterogeneous in-
terplay between the human host and Mtb [6].
In order to provide better insights into this intricate host-pathogen
interaction and to discover new Mtb antigens as vaccine candidates and
TB biomarkers, searches for novel and relevant Mtb antigens have been
intensified during recent years, particularly following the application of
genome wide approaches. In this paper, after a short review of past
methodologies, we summarize and discuss several important recentMtb
antigen discovery studies that have harnessed the unprecedented op-
portunities of “unbiased” genome wide approaches. We compare their
results, discuss those Mtb antigens that were discovered independently
by different approaches, and present a comprehensive overview of Mtb
protein and peptide antigens.
1.1. Traditional Mtb antigen discovery approaches in the last century
Traditional Mtb antigen discovery approaches in the pre-genomics
era relied on classical biochemical analyses of in vitro culturedMtb from
which fractions and secreted moieties were isolated and purified [7],
based on much excellent work from many researchers. The antigenicity
of the isolated components was typically tested using cells or sera from
Mtb infected animals, including mice, rabbits, goats and cattle, as well
as human beings exposed to mycobacteria such as LTBI, BCG vaccinees
and active or treated TB patients. After the discovery of IFN-γ as an
important cytokine in protective immunity to TB in animal models and
humans [8,9], and the development of suitable assays to measure it, the
antigenicity of Mtb antigens started to be determined increasingly by
the ability to induce IFN-γ in mouse models and in blood cells of Mtb
exposed individuals in vitro, assuming that IFN-γ could be a correlate of
protection. These approaches in the 1980′s and 1990′s led to the
identification of important Mtb antigens abundantly expressed in vitro,
including Ag85C (fibronectin-binding protein C, Rv0129c), Ag85B
(Rv1886), Ag85A (Rv3804c) [10–12], Mpb64 (Rv1980) [13], 38kDa
(Rv0934) [14], ESAT-6 (Rv3875) [15], Mtb8.4 (Rv1174) [16], CFP-10
(Rv3874) [17], Mpt51 (Rv3803c) [18] and TB10.4 (Rv0288) [19].
Virtually all of these proteins were secreted Mtb proteins, and therefore
amenable to identification in the supernatants of in vitro grown Mtb. In
addition, also heat shock proteins became a prominent focus of atten-
tion as will be discussed below.
The completion of the sequencing and annotation of the Mtb
(H37Rv) genome in 1998 [20] in the first decade of this century was
key to the initiation of the first Mtb post-genomic approaches, and al-
lowed the discovery of new classes of Mtb antigens using unbiased
approaches. One example of such approaches is the discovery of so
called Mtb “latency antigens”, based on genome-wide expression pro-
filing of Mtb bacteria in vitro exposed to hypoxic culture conditions.
1.2. Mtb latency antigens are important tools for designing new, and for
improving current TB vaccines
By using in vitro conditions that mimic the host environment en-
countered by Mtb during in vivo infection, such as hypoxia, nutrient
starvation or IFN-γ-activated macrophages, a genetically regulated
metabolic shift down was discovered in Mtb bacilli exposed to such
conditions. Mtb down regulated most of its genes as an adaptive re-
sponse to stress, but this app eared to be accompanied by a remarkable
upregulation of the expression of 48Mtbgenes in response to various
environmental stress factors including hypoxia. These genes were found
to be regulated by a response regulator termed the DosR protein (en-
coded by Rv3133c) and hence this regulon was called the dormancy or
DosR regulon [21,22]. One of the genes most strongly upregulated was
Rv2031c/α-crystallin, which is involved in cell wall thickening and
stabilisation under hypoxia (further discussed below). The DosR reg-
ulon encoded gene products were designated “latency antigens” and
were tested as recombinant proteins for cellular and humoral recogni-
tion in LTBI individuals and TB patients from different geographical
cohorts in Europe, Africa, South America and India. In all cohorts, the
Mtb latency antigens were recognized preferentially by LTBI donors
compared to (active or treated) TB patients, in terms of both cellular
and immunoglobulin responses [23–28]. The data suggested that sev-
eral of these antigens such as Rv1733c, Rv2029c, Rv2626 and R2628
could be useful antigenic targets to discriminate LTBI from TB patients,
which is not well possible by IGRA or TST (Supplementary Table 1).
Moreover, the fact that the BCG genome contains homologues of the
DosR genes [29] suggested that latency antigens might be interesting
TB booster vaccine candidates, particularly since they have been de-
monstrated in several studies to have protective efficacy in different
animal models [30–34]. However, a puzzling observation was that
neither subcutaneous (sc) BCG vaccination in animals, nor intradermal
(id) BCG vaccination in humans was found to induce T cell responses
against latency antigens, suggesting that these routes of immunisation
might not allow BCG to enter a state of latency [29,35].
We have hypothesized that the inability of BCG to induce immune
responses to latency antigens may underlie its impaired ability to in-
duce full protective immunity to Mtb. We have submitted the hypoth-
esis that this should be repaired, either by recombinant overexpression
or by subunit vaccine boosting, in order to induce improved protection.
Our results [36] are in support of this concept, since an Rv1733c,
Rv3407 and Rv2659 (representing latency and starvation antigens)
expressing recombinant BCG strain (rBCGΔureC::hly) induced better
protection against highly virulent Mtb(Beijing) in mice than did the
regular recombinant BCG (rBCGΔureC::hly) lacking these antigens. In
addition, our more recent data have demonstrated that Rv1733c vac-
cination following BCG significantly improved the protective efficacy of
BCG [33].
Another important latency antigen discovered around the same time
was the 28kDa heparin-binding protein (HBHA, Rv0475), an antigen
not regulated by DosR. The HBHA adhesin, identified using heparine-
Sepharose chromatography from culture supernatant and extracts of
Mtb and M. bovis [37], is expressed on the surface of Mtband promotes
its interaction with non-phagocytic cells, thereby facilitating Mtb ex-
trapulmonary dissemination [38]. It has been shown that when coated
with anti-HBHA antibodies Mtb has a reduced ability to disseminate
outside the lung in mice, suggesting that anti-HBHA antibodies in TB
patients might help containing Mtb infection by blocking HBHA [38].
Interestingly, stimulation of lymphocytes from LTBI but not TB patients
with HBHA induced IFN-γ secretion [39,40] and perforin-producing
CD8+ T cells cytotoxic against mycobacterium infected macrophages
[41]. Based on these findings, HBHA induced T cell IFN-γ production
has been proposed as a biomarker of LTBI [42]. In addition, HBHA has
been shown to enhance BCG protective efficacy both in adult and new-
born mice when administrated in prime-boost regimens [43,44]. These
data, supported by the evidence that BCG induces specific HBHA multi
cytokine responses [45], suggest that HBHA might be part of a pro-
mising TB subunit vaccine candidate to boost BCG.
In conclusion, latency antigens (DosR regulon encoded antigens,
HBHA) are highly potent novel Mtb antigens, which could find appli-
cation in the design of new TB vaccines (see also below) as well as in
tests diagnosing LTBI.
1.3. Mtb resuscitation-promoting factors (Rpf) are antigens that are
promising targets for diagnosis and vaccination
Next to latency antigens another class of Mtb antigens discovered
were Mtb’s Rpfs [46,47]. Rpfs are secreted bacterial proteins that have
hormone like activity, and are able to promote the transition from a
dormant into an active e replicating state of bacteria, including myco-
bacteria [48]. The five Mtb Rpfs, specifically RpfA (Rv0867c), RpfB
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(Rv1009), RpfC (Rv1884c), RpfD (Rv2389c), and RpfE (Rv2450c) were
screened for immunological reactivity in Mtb exposed individuals and
found to be recognized in vitro by IFN-γ producing cells preferentially
from LTBI [28,49,50]. Based on this property, these proteins could
further help differentiating LTBI from TB, next to the above latency
antigens.
1.4. New developments for TB vaccines with latency and Rpf antigens in
NHP and mouse models
From the TB vaccine perspective, several of the above discussedMtb
antigens (Rpfs, latency antigens and early secreted proteins) have been
evaluated recently as combinatorial, multistage vaccines in mice and
rhesus macaques. Vaccination with a virally (i.e. modified RhCMV)
vectored combination of 6 or 9Mtbantigens in Rhesus macaques
strongly reduced mycobacterial loads in the lung of the Mtb infected
animals, even to the unprecedented extent of sterile eradication in half
of the animals [51–53]. The RhCMV vectored insert contained 6 or
9Mtbantigens, namely: Ag85A, Ag85B, ESAT-6, Rv1733c, Rv2626c,
Rv3407, RpfA, RpfC, and RpfD [53]. Additionally, 5 of these antigens
have been evaluated recently as part of another multi-antigenic vec-
tored vaccine, MVATG18598, in this case in post-exposure BALB/c and
C57BL/6 mouse models [54]. MVATG18598 specifically expressed
Rv2626c, Ag85B, CFP-10, ESAT-6, TB10.4, Rv0287, RpfB, RpfD,
Rv3407, and Rv1813c. Mice were challenged with Mtb, treated with a
standard antibiotic regimen (rifampin, isoniazid and pyrazinamide) and
then “therapeutically” vaccinated. Two different vaccination regimens
(i.e. during and after chemotherapy), two delivery routes (s.c. or i.n.)
and different numbers of injections (1x, 3x, 5x, and 7x) were tested to
evaluate the effect of MVATG18598 in this post-challenge model. The
s.c. administration (3x) of MVATG18598 during treatment showed the
strongest reduction in the occurrence of post treatment TB relapses and
Mtb burden in BALB/c mice. This finding was confirmed in C57BL/6
mice (in which only 1x injection of the vaccine was tested). In both
mouse strains, the MVATG18598 vaccination triggered strong IFN-γ
production and high levels of polyclonal antibodies against specific
components of the multi-antigenic vaccine.
These preclinical TB vaccination data from NHP and mouse confirm
and extend the unexpectedly strong vaccine potential of the newly
discovered latency, early secreted and Rpf antigens, and hold promise
for application in humans in the nearby future, in both preventive and
therapeutic fashion.
1.5. Results from latest clinical trials with new TB subunit antigen based
vaccines and BCG. Implications for developing new vaccines
To date, there are only three clinical studies that have reported
human efficacy data following vaccination with Mtb antigen-based
subunit vaccines. One was from a large phase IIb trial conducted with
MVA85A expressing the early secreted protein Ag85A. Unfortunately,
this candidate failed to induce additional protective efficacy against
developing TB (in a PoD (prevention of disease) trial design) following
initial standard BCG vaccination in children [55]. In a more recent,
prevention of infection (PoI) clinical study in the same area, H4 (a fu-
sion protein of secreted antigens Ag85B/TB10.4) was administered in
Th1 inducing IC31 adjuvant to previously BCG vaccinated adolescents.
Although H4:IC31 failed to prevent initial or sustained Mtb infection
significantly, a clear trend towards reduced sustained infection (defined
as three consecutive positive IGRA tests) was distinguishable in this PoI
trial, providing a first “signal” for a TB subunit vaccine. Unexpectedly,
and encouragingly however, in this study BCG revaccination gave a
significant reduction in sustained infection as determined by three
consecutive positive QFG/IGRA tests [56]. This could be interpreted as
suggesting that immunity can be induced by vaccination that can
control or even eliminate Mtb, and calls for follow up studies.
Both MVA85A and H4:IC31 vaccines were designed principally to
boost prior BCG induced CD4+ Th1 immunity. The lack of significant
efficacy against the primary clinical endpoints could be interpreted as
indicating that, while CD4+ Th1 cells are clearly essential they may
not be sufficient to induce adequate protection. This agrees with the
finding that frequencies of IFN-γ-expressing cells did not correlate with
BCG induced protection in a South African population of infants [57].
Alternative explanations obviously are possible but a detailed discus-
sion of that topic falls outside the scope of this review.
Finally, the third and most recent clinical data from a TB subunit
PoD trial come from the M72 (GSK) trial, which administered a fusion
protein called M72 (consisting of rearranged antigen fragments from
Rv1196 and Rv0125) adjuvanted in the Th1 promoting AS01E. The
results of this seminal study will become available mid-2018.
Thus, despite some initially disappointing results there is hope for
new and properly delivered TB subunit vaccines. Also clear signals from
live mycobacterial “whole cell” vaccines are emerging, including re-
combinant BCG strains [58] and attenuated Mtb strains (no clinical
efficacy data are yet available, although the MTBVAC vaccine was re-
portedly safe) [59]. This will not be discussed further here.
2. Broadening the discovery of the Mtb antigenome using genome
wide approaches
Advances in DNA technologies, genome sequencing and bioinfor-
matics tools now offer unprecedented opportunities to rapidly and ex-
haustively mine the potential Mtb antigenome, at least at the proteome
level. Here, we will focus chiefly on the most representative recent
studies and discuss their results.
The first whole genome based Mtb antigenome search was in-
novative in that it generated the first Mtb genome expression libraries
using newly developed recombinant DNA technologies. This Mtb
genome expression library was built by shearing Mtb Erdman strain’s
DNA, that was subsequently linked to EcoRI linkers and inserted into
ʎgt11 vectors, allowing access to Escherichia coli's transcriptional and
translational machinery to produce Mtb protein fragments [60]. The
potential to detect “all” (note: the library almost certainly was in-
complete) Mtb proteins, including those not always expressed by Mtb
depending on its phase, constituted an important novelty. By screening
this library with murine monoclonal antibodies [61–63] and polyclonal
sera [64,65] several new Mtb proteins such as HspX/ α-crystallin
(Rv2031c) were identified and further validated using lymphocytes or T
cell clones from TB patients [66]. In addition, also other heat shock
proteins such as hsp60 (Rv0440) and hsp70 (Rv0350) [62,67,68] were
extensively studied, in part due to their high immunogenicity and in
part due to their sequence similarities with mammalian hsp, raising the
interesting possibility of being involved in inducing cross-reactivity and
the subsequent precipitation of auto-immunity [69–71].
Expression cloning technologies used in subsequent studies, in-
cluding those employing DNA from virulent Mtb strains [72], resulted
in the discovery of additional immunogenic proteins comprising
Rv1510 [72], Mtb39a (Rv1196) [73], Mtb32a (Rv0125) [74], Mtb9.9a
(Rv1793c) [75], Mtb9.8 (Rv0287) [76] and Mtb41 (Rv0915c) (Sup-
plementary Table 1) [77–82]. Obviously, these methods are biased to-
wards protein antigens and do not offer the possibility to evaluate non-
protein antigens like polysaccharides, lipopolysaccharides, and glyco-
lipids. In addition, the gene products synthesized by recombinant ex-
pression in heterologous hosts does often not replicate post-transla-
tional modifications such as lipidation and glycosylation, which are
naturally occurring in mycobacteria. Whether and how those changes
impact protein immunogenicity has been studied to some extent, and it
was recently shown that glycoconjugate derivatives of Ag85B, obtained
after glycosylation of its lysine residues, were less recognised by BCG
vaccinees and TB patients compared to the unmodified variant [83].
This finding suggests that recombinant products lacking post-transla-
tional modifications could lead to misinterpret the immunological ac-
tivity of antigens compared to the variants present during natural Mtb
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infection. The use of other vectors phylogenetically closer to Mtb, such
as M. smegmatishas been proposed as an alternative host to overcome
such post-translational issues [84].
Although allowing the identification of the Mtb antigens Rv1196
and Rv0125 which are now included in an advanced TB vaccine can-
didate, M72/AS01E (see above) [85, 86], the above discussed Mtb
genome expression libraries have nevertheless unlocked only a small
portion of the Mtb antigenome (Supplementary Table1). This is prob-
ably due to issues of low expression in heterologous systems and the use
of small DNA fragments, precluding the expression of conformationally
more complex structures such as antibody epitopes.
This scenario was revolutionized by the completion of the Mtb
genome sequence that now permitted access to the entire Mtb protein
antigenome [20]. TheMtb genome sequence made it possible to identify
novel candidate antigens without the need for, and limitations of
having to cultivate Mtb [7]. A breakthrough was also that all genome
information was made available via open-source internet genomic and
proteomic databases such as TubercuList (http://svitsrv8.epfl.ch/
tuberculist/) and later TB Database (www.tbdb.org) [87]. In addition,
the increasing accessibility of highly powerful bioinformatics tools now
also allowedin silicogenomic analyses and comparative evaluation (e.g.:
BLAST, https://blast.ncbi.nlm.nih.gov/Blast.cgi), and to predict new
Mtb T cell epitopes based on predictive HLA binding motifs (e.g.:
ProPred, http://crdd.osdd.net/raghava/propred/, HLA_BIND, https://
www-bimas.cit.nih.gov/molbio/hla_bind/, EpiMatrix, http://i-cubed.
org/tools/ivax/ivax-tool-kit/epimatrix/, DTU prediction servers,
http://www.cbs.dtu.dk/services/). These developments and technolo-
gies have revolutionized the field of antigen discovery in general, and
that ofMtb in particular (Mtb is a complex pathogen to work with due to
its slow growth, its phase variation and its restriction to BSL3 safety
level laboratories).
3. Mining the complete Mtb antigenome for epitope and antigen
discovery
3.1. In search of new Mtb Epitopes using peptide libraries
Experimental methods to identify new Mtb (peptide) epitopes have
been classically based on the screening of overlapping peptides span-
ning the full sequence of the relevant target proteins, followed by as-
saying antibody and/or T cell immune responses in in vitro assays and/
or in vivo models [88–94]. This approach has also been applied to in-
terrogate novel interesting candidate antigens selected from the whole
Mtb genome sequence. Some of the most studied proteins have been
those encoded by the so-called regions of differences (RDs). RDs were
identified by comparative genome analysis and consist of 16 genomic
segments that are present in Mtb (H37Rv strain) but absent from most
BCG vaccines and non-tuberculous mycobacterial strains [95–97]
(Supplementary Table1). Although those genomic regions together
encode 129 predicted open reading frames (ORFs), only a few of these
have been studied in detail -at least according to accessible published
information. Moreover, those that were translated into approved TB
diagnostic tests had already been discovered through conventional
approaches described above [98]. Very recently only, a new over-
lapping peptide cocktail covering the RD7 encoded esx member antigen
Rv2348 in combination with CFP10 and two other secreted proteins
(EspC (Rv3615s) and EspF (Rv3865)) was successfully evaluated using
this approach, and subsequently developed into an ESAT-6 free diag-
nostic IGRA test [99]. The ESAT-6 family comprises 23 small proteins
(from EsxA to EsxW) that are mostly secreted in pairs (with the only
exception of EsxQ). Not only ESAT-6 or CFP-10 but also other members
of the ESAT-6 family are highly antigenic as demonstrated across sev-
eral independent post-genomic studies (Supplementary Table 1, Figure
1). Furthermore, several ESAT-6 family members were found to have
strong vaccine efficacy in mouse models: immunization with the fusion
protein H65 (containing the ESX dimer substrates EsxD-EsxC, ExsG-
EsxH, and ExsW-EsxV) had comparable protective efficacy with BCG
[100].
3.1.1. Conventional HLA class I restricted CD8+ T cell targeting peptide
libraries and predictive algorithms: complementary approaches successfully
identify Mtb epitopes for Mtb specific CD8+T cells
Other new candidate Mtb antigens were studied for antigenicity
using conventional peptide arrays. These candidates were selected
based on specific criteria such as MHC binding algorithms that were
used to mine public genomic databases (mainly TubercuList) or pub-
lished proteomic/transcriptomic data obtained from in vitro Mtb in-
tracellular cultures. One of the first libraries built on such an approach
consisted of 15-mer peptides covering the sequences of 389 proteins
[101], and aimed to identify CD8+ T cell stimulating epitopes by using
a small panel of human CD8+ T cell indicator clones restricted to the
classical HLA class Ia alleles B*5701, B*3905 and B*3514. The proteins
included were selected based on three parameters: (i) gene products
described in TubercuList as “PPE/PE”, “cell wall and cell processes”,
“virulence, detoxification, adaptation” and “secreted”, (ii) genes highly
expressed during in vitro Mtb intracellular infection, and (iii) genes not
expressed by BCG strains. This resulted in the synthesis of 39,499
peptides, which were then pooled and tested for T cell recognition by
IFN-ɣ ELISPOT. The peptide pools were screened in the presence of up
to nine different CD8+ T cell clones from two different donors (one TB
patient and one LTBI), autologous dendritic cells and IL-2. In this way,
new CD8+ epitopes encoded by the Mtb antigens EsxJ (Rv1038c), PE9
(Rv1088) and PE_PGRS42 (Rv2487c) could be identified (Supplemen-
tary Table1). When this same 15-mers library was screened with a panel
of more than 30 non-classically HLA class I (that is: non-HLA class Ia
A,B or C) restricted Mtb-reactive CD8+ T cell clones, no epitopes pre-
sented by the HLA class Ib molecules MR-1 or HLA-E were found.
Recently, the same peptide library has been tested again in IFN-ɣ
ELISPOT assays usingex-vivoperipheral blood CD8+ T cells from 20
ethnically diverse individuals including5 TB patients and 15 LTBI do-
nors [102]. That study did not show differences in the magnitude of
response between TB and LTBI, but validated 17 know CD8+ T cell
epitopes and identified several new ones scattered across 58 antigens
(Supplementary Table 1). Peptide pools were considered im-
munodominant when able to induce positive IFN-ɣ ELISPOT responses
in 3 or more Mtb exposed individuals. Four antigens, specifically PPE15
(Rv1039c), PPE51 (Rv3136), PE12 (Rv1172c) and PE3 (Rv0159c),
discovered in this CD8+ T cell library and three of them independently
by other two post-genomic approaches (discussed below) (Fig. 1)
[103,104] have been recently evaluated for protective efficacy in
C57BL/6 and BALB/c mice models using a ChAdOx vector platform
[105]. Two of them, PPE15 and PPE51 were able to reduce the Mtb
pulmonary load as stand-alone vaccines, but only PPE15 boosted BCG
protective efficacy in the C57BL/6 (but not in BALB/c) mice. The
reason why antigens selected using similar criteria (based e.g. on
protein category, antigenic or immunogenic properties) have different
protective effects in vivo is a common finding but still not fully under-
stood.
3.1.2. HLA restricted CD8+ and CD4+ T cell targeting peptide libraries
based on in silico predictive algorithms successfully identified epitopes for
Mtb specific CD4+ and CD8+ T cells
In silico epitope prediction programs, even when unable to consider
the effects of 3D peptide structures, post-translation modifications or
alternative peptides sequences generated by proteasome-catalyzed
splicing [106,107], can be used to select putative antigenic peptides
without the need to screen the entire amino acid (aa) sequence of target
proteins. Using these bioinformatics tools, novel CD8+ or CD4+ T cell
epitopes of known Mtb proteins were found, which were validated by
MHC binding assays and reactogenicity of lymphocytes from Mtb ex-
posed individuals, and/or used to generateMtb epitope specific induced
T cell clones [108–112]. These pioneering studies, although limited to
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previously studied Mtb proteins and to the most common HLA alleles,
provided the proof of concept for later application ofin silico epitope
screenings to the fullMtb antigenome. In search of new potential CD4+
T cell epitopes, 73 secreted proteins were directly selected from theMtb
genome and screened for HLA-II binding motifs [113]. The positive hits
were then ranked and the top 17 novel peptides synthesized. One of
these epitopes (belonging to the Rv2223c protein) was promiscuously
and broadly recognized by IFN-γ producing peripheral blood cells
(PBMC) from LTBI donors (n=11) (Supplementary Table 1) and proved
to be immunogenic in HLA-DR B*0101 transgenic mice when ad-
ministered in a DNA plasmid vector co-expressing other 23 Mtb epi-
topes previously identified.
Using a similar approach, which instead was CD8+ T cell epitope
oriented, 235Mtbproteins were screened using genome-based bioin-
formatics for potential binding peptide epitopes to HLA-A2, -A3, and
-B7 as HLA class Ia superfamily members [114]. The Mtb proteins in-
cluded were: (i) proteins already used in TB vaccine trials, (ii) proteins
with already known CD8+ T cell epitopes, (iii) proteins with the
Fig. 1. Overlap among Mtb antigens identified by independent genome wide strategies.
Mtb antigens identified by at least two independent genome wide strategies (discussed in this review) are shown in this heat map. The methods included are indicated
with number from 1 to 14 (the respective references are specified in the last row and in the legend). The colours assigned to each Rv number follows the division of
the functional categories described in the TubercuList database (details in the legend). Additional information regarding these proteins (gene names, protein lengths,
being encoded by genes belonging to the Regions of Differences (RD) or to the ESAT-6 family and the expression profile of the encoding genes identified by RNA
isolated from the lung of Mtb infected mice and from the sputum of TB patients in relation to in vitro cultured Mtb H37Rv) are also accessible in this Figure.
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highest HLA class I binding prediction values, (iv) conserved proteins,
(v) proteins encoded by theMtb DosR regulon, (vi) proteins with known
B cell epitopes, (vii) secreted proteins, and (viii) proteins predicted to
be secreted [114]. Out of 432Mtb9-mer peptides tested, 70 (of which 58
were unknown epitopes) were found to induce proliferative responses
in CD8+ T cells from two or more individuals out of the 41 purified
protein derivative responder (PPD+) healthy donors screened. Based
on the frequency and the magnitude of CD8+ T cell responses, 18 out
of these 70 epitopes, mainly including peptides from secreted antigens,
were then selected for further testing in ten HLA-A*0201 positive TB
patients and an equal number of HLA-A*0201 positive controls, using
Mtb specific petide/HLA-A*0201 tetramers and functional peptide sti-
mulation assays. All 18 selected epitopes were confirmed to be anti-
genic in TB patients (but not negative controls) as visualised by specific
tetramer staining, and to induce specific poly functional (IFN-γ+/IL-
2+/TNF-α+) CD8+ T cells (Supplementary Table 1). Of note, half of
the 18 proteins encoding these epitopes had also been screened in the
15-mer CD8+ peptide library mentioned above, but only three antigens
(Rv1966, Rv1997 and Rv2780) were found in both approaches to
contain Mtb antigenic peptides stimulating CD8+ T cells (Fig. 1). This
significant yet limited overlap could be explained by differences in the
design of the two studies: the criteria applied to determine potential
Mtb antigens (this resulted in only 56 putative antigens shared between
the ones selected in both studies), the length of the peptides generated
from these proteins (9-mers vs. 15-mers), the way in which the peptides
were evaluated (single peptides vs. peptide pools), and the read-outs
chosen to evaluate the immunodominance of the peptides (proliferation
/ CD8+ poly functionality / HLA class Ia tetramer staining in the
second vs. the use of selected T cell clones / IFN-γ ELISPOT in the first
study).
The first in silico genome-wide screening which did not apply an
arbitrary criteria driven selection of Mtb proteins was performed in
search of putative HLA-B*3501 T cell stimulating Mtb epitopes [115].
This allowed the identification of both known as well as novel antigens
(Rv0670, Rv1280c, Rv1464, Rv1641, Rv2182c, Rv2476, Rv2823c,
Rv3378c and Rv3689) encoding new epitopes recognised by CD8+ T
cells from BCG vaccinated healthy donors in the context of one single
HLA allele (Supplementary Table 1). Another study, applying a similar
methodology but restricted rather to HLA-A*0201, discovered two
other new antigens (Rv1490 and Rv1614) that contained CD8+ T cell
stimulating epitopes, and that were recognized by CD8+ T cells from
LTBI and TB patients (Supplementary Table 1) [116].
3.1.3. Additional across genome epitope predictions identify many novel
Mtb epitopes for CD4+ T cells
*With the better definition of HLA-I supertypes and corresponding
alleles [117], the increased knowledge of the global distribution of the
most common HLA-II molecules [118], and the availability of addi-
tional Mtb genome sequences, the comprehensiveness and sizes of HLA
allele based in silico epitope predictions for Mtb sharply increased. One
Fig. 1. (continued)
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of the largest in silico genome-wide screening efforts used an approach
parsing all predicted protein sequences of 21 Mtb strains into all their
possible 15-mers and subsequently selecting the most conserved and
best-predicted promiscuous binders for 22 different HLA-DR, -DP and
-DQ class II alleles [104]. A total of 20,610 peptides was then selected
for synthesis and tested in pools of 20 peptides to assess the in vitro IFN-
ɣ response elicited in PBMC of 28 LTBI donors by ELISPOT. Based on
peptide pools recognised by three or more LTBI donors, 369 individual
Mtb epitopes, covering 82 different Mtb antigens, were identified
(Supplementary Table 1). Of note, it was reported that 47% of those
peptides accounted for 90% of the total responses. By depleting PBMC
of either CD4+ or CD8+ T cells it could be confirmed that 97% of the
epitopes were recognized exclusively by CD4+ T cells. It is not fully
clear why so few CD8+ T cell epitopes were found, but suboptimal
peptide length and assay criteria might have contributed to favouring
CD4+ T cell epitope identification. In any case, out of the 82 Mtb an-
tigens, 34 were recognized as CD4+ T cell targets for the first time. The
majority of the Mtb antigens identified were associated with most ca-
tegories indicated in TubercuList, but with a relative overrepresentation
of antigens from the PE/PPE family, a large and unique family of genes
representing over 10% of the entireMtb genome [20]. Interestingly, the
authors introduced the concept of antigenic clusters which they defined
as groups of at least 4 proteins recognized by at least two LTBI donors
and encoded within a 5 gene-interval. Based on this approach, they
then identified three antigenic islands that mainly included known
components of the type VII secretion systems (T7SS) Esx-1 and Esx-3,
and ten novel antigens were reported for the first time. The researchers
then further investigated the antigenicity of those new peptide pools by
cytokine induction (IFN-γ/TNF-α/IL-2) and by assessing T cell memory
phenotypes. No differences in cytokine production were observed be-
tween the proteins identified [104]. Of particular interest, the authors
found a new memory CD4+ T cell subset to be involved in the re-
cognition of Mtb antigens in LTBI donors. This Th1* cell subset ex-
pressed a unique, CD4+CXCR3+CCR6+CCR4- phenotype, and had a
lineage-specific transcriptional signature shared with both Th1 (such as
T-bet (TBX21), granzymes A and K, perforin (PRF1), and the tran-
scription factor EOMES) and Th17 (RORC, DAM12, PTPN13, and
IL17RE, the receptor for IL-17C) cells [119]. Furthermore, the
CD4+CXCR3+CCR6+CCR4− T cells selectively expressed genes in-
volved in cytokine/receptor interactions (CCR2, IL12RB2, IL23R, KIT
[CD117, c-Kit], BAFF [CD257, TNFSF13B]), cell persistency and pro-
liferation (i.e., BAFF, MDR1 (ABCB1), and KIT) as well as genes pre-
viously reported associated with TB susceptibility (CCR2 and IL12RB2).
In addition to IFNG, TNF and IL2, the activated
CD4+CXCR3+CCR6+CCR4− T cells expressed cytokine transcripts
(CSF1/2, CCL3/4, GZMB, IL6/17A/22, CXCL9, and VEGFA, CSF1 (M-
CSF) and GM-CSF) many of which have been shown to play a role in TB
containment previously. This makes these CD4+ T cell subsets also
interesting as potential Mtb specific correlates of protective immunity.
Screening large cohorts of Mtb exposed individuals in different
geographic settings obviously is essential to corroborate the anti-
genicity of Mtb peptides whose immunodominance has been based on
positive IFN-γ responses limited to few donors in a single site. To ac-
complish this, 15-mer peptide pools (20 per protein per pool) of 25
novel antigens identified in the last study described were further ex-
amined by ELISPOT in 128 LTBI from nine different geographical lo-
cations. Importantly the results validated the antigenicity of the se-
lected epitopes [120]. It is interesting to note that peptide pools from
four novel antigens (Rv1172c, Rv1788, Rv1791, and Rv3135) that were
shown to be recognised by (presumably CD4+T cells from) most of the
LTBI cohorts, were among those subsequently described to contain also
CD8+T cell epitopes in another study (Fig. 1) [102]. Recently, IFN-γ
based recognition of 40 Mtb antigens identified in the previously de-
scribed CD4+ library together with 20 Mtb antigens selected from
other studies was evaluated in a diluted whole blood assay in Atlanta
and Kenya [121]. The peptide pools of proteins previously described as
antigenic (such as Rv1172c and Rv1872c among others) did not always
induce high IFN-γ responses in the cohorts of LTBI, TB household
contacts and TB patients included in this study. This difference could be
explained by the different composition of peptide pools used (18-mer
based), the read-out implemented (1:4 diluted whole blood stimulated
7 days with 1ug/ml), environmental or genetic (HLA) differences be-
tween the populations, amongst others.
The in vitro reactogenicity of human T cells to Mtb peptides re-
stricted to diverse HLA molecules can indeed be highly heterogeneous
due to the extensive HLA polymorphisms [122]. To solve those lim-
itations, a recent study tested a peptide pool of 300 Mtb epitopes and
showed that this comprehensive megapool, consisting of peptides from
52 Mtb antigens (including 45 antigens discovered in the above de-
scribed CD4+ peptide library, of which 7 were also evaluated as pep-
tide pools in the 9 different cohorts of LTBI discussed above), accounted
for 80% of Mtb-specific T cell responses in LTBI, including adults and
adolescents [123]. The study cohort included LTBI with and without a
self-reported history of active TB. Interestingly, the Mtb epitope re-
activity, based on IFN-γ ELISPOT and intracellular cytokine staining,
was around 10-fold lower among subjects that had experienced past TB
disease in the last 6 years, for a specific set of epitopes, which was
designated “type 2” or “post TB sensitive” Mtb epitopes [124]. No such
difference was found for “type 1” or “persistent” epitopes, which were
recognized equally well by LTBI with or without previous TB. Con-
founding factors such as an active TB disease process (which was
evaluated by comparing responses between type 1 and type 2 epitopes
in 16 TB patients), differences in T cell memory phenotypes, or dif-
ferences in gene expression in responding T cells could be excluded.
Also numbers of in silico predicted HLA-II binding motifs did not differ
among the different classes of epitopes. The only difference found was
that Mtb epitopes that were less recognised by LTBI with past-TB were
those with the highest sequence homologies to proteins from the human
microbiota or from nontuberculous mycobacteria (NTM). Based on
their data, the authors concluded that the diversity in type 2 epitope
reactogenicity among LTBI with or without past TB could be related to
changes induced in the microbiota by TB treatment, although some
mycobacterial specific proteins, such as ESAT-6 or CFP-10, still con-
tained several type 2 peptides. Data on the microbiota compositions of
TB patients followed pre-, during and after treatment will, however, be
needed to validate this hypothesis. It would also be important to de-
termine the general homology between other proposed Mtb antigens
and the human microbiota. The fact that NTM homologous Mtb epi-
topes were found to be less reactogenic in the post-TB donor group is
also quite intriguing especially considering previous reports showing a
strong reactogenicity to such epitopes in LTBI and in healthy in-
dividuals from non-endemic areas [125]. Moreover, the low recognition
of NTM homologue epitopes in the post-TB LTBI donors is in line with
the finding that other NTM homologues, such as the DosR regulon
encoded proteins [126], are less recognized in treated TB patients than
in LTBI [23]. A role for NTM exposure in inhibiting BCG vaccine in-
duced protective immunity has been repeatedly proposed [4] and ex-
perimentally proven in mouse models [127]. The relation to the phe-
nomenon of type 2 epitope remains to be clarified.
3.1.4. Unconventional HLA class Ib restricted CD8+T cells: identification
of Mtb epitopes for CD8+T cells genetically restricted by HLA-E, with an
unusual phenotype and function
Alternatively to conventional HLA-I and HLA-II binding motifs,
peptides presented by non-classical HLA molecules have been proposed
as interesting Mtb antigenic targets. For HLA-E only 2 coding variant
molecules are known, which differ in a single amino acid localized
outside the peptide binding groove. Thus, HLA-E molecules can essen-
tially be seen as virtually monomorphic antigen presentation molecules,
suggesting the interesting possibility that a relatively small number of
Mtb peptides can be used for presentation via HLA-E for e.g. vaccination
purposes. Based on initial evidence that HLA-E molecules could present
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Mtb derived peptides to two human T cell clones [128], the Mtb
(H37Rv) genome was screened in silico for candidate epitopes predicted
to bind to HLA-E molecules [129]. This effort resulted in the selection of
69 potential HLA-E binding peptides, which were tested for HLA-E
binding and CD8+T cell recognition (by T cell proliferation and cy-
tokine induction) in PPD+donors, PPD- healthy controls, BCG vacci-
nated infants and cord blood samples (Supplementary Table 1). Un-
expectedly almost all predicted epitopes could be validated and some
were recognized by as many as 40% of the PPD+ responsive donors.
Several epitopes were also recognized by the BCG vaccinated infants
from South Africa, but not by cells from cord blood, suggesting vaccine
induced T cell memory. Subsequent investigations focussed on the most
frequently recognized immunodominant HLA-E presented Mtb peptides
using T cell clones. This analysis revealed that these HLA-E restricted
CD8+ Mtb specific T cells had a Th2 like phenotype and function. This
was confirmed in the circulation of TB patients and LTBI [130–132].
Although numbers were small, there was a tendency towards higher
frequencies of HLA-E restricted Mtb specific T cells in TB/HIV coin-
fected individuals. Using a new expansion protocol these results could
be corroborated using HLA-E tetramers combined with specific func-
tional phenotyping in the blood of TB patients and LTBI [132]. The low
polymorphism of the HLA-E locus and the stable expression of the HLA-
E molecule even upon infection with HIV may render HLA-E peptides to
be attractive antigenic targets [133].
In this context it is relevant to mention that several of the Mtb
peptide specific HLA-E restricted T cell clones inhibited Mtb growth in
human macrophages, in line with a possible protective function.
Furthermore, several studies in animals now suggest that HLA-E like
Qa-1 restricted CD8+T cells contribute to protective immunity in vivo.
The murine homologue of HLA-E, Qa-1, was found capable of pre-
senting the same HLA-E bindingMtb peptides to CD8+ T cells, and Qa-1
knockout mouse were more susceptible to Mtb and died earlier with
higher bacterial burdens [134]. This was not due to engagement of NK
receptors, as demonstrated in genetic ablation experiments. In addition,
as mentioned above, NHP vaccination studies with genetically modified
RhCMV vectors expressing Mtb antigens revealed that MHC-E restricted
T cells can be induced and mediate part of the strongly protective re-
sponse against TB I the NHP model [53]. Clearly HLA-E restricted T cell
immunity needs to be investigated in more detail in the context of TB
vaccination.
Besides HLA-E restricted T cells there are also other groups of so-
called donor unrestricted T cells or DURT T cells [135]. These cells are
mostly CD8+T cells that are genetically restricted by highly con-
served, non-polymorphic presentation molecules: MR1 (presenting
metabolites to mucosal associated invariant T cells or MAITs); CD1a, b
and c molecules presenting mostly lipid antigens; NKT cells restricted
by CD1d; TCRγδ cells, some which recognize phospho-antigens in the
context of butyrophilin 3A1. However, none of these cells recognize
peptide antigens and therefore are not discussed in detail in this review,
which focuses on postgenomic Mtb protein and peptide antigen iden-
tification.
3.1.5. Hyperconserved or variable Mtb epitopes
Most of the studies discussed so far have aimed at identifying im-
munodominant Mtb peptides and protein antigens for T cells. However,
the focusing of T cell responses exclusively on conserved im-
munodominant epitopes has been under discussion lately after human T
cell Mtb epitopes were found to be evolutionary more conserved than
essential Mtb genes as a whole, or than the non-epitope encoding se-
quences of the same Mtb antigens [136] (in this work 491 experimen-
tally verified peptides were studied covering 78 Mtb antigens). This
discussion impacts also TB vaccine development strategies since it was
proposed that the observed T cell epitope hyper conservation suggested
that natural T cell immunity might be beneficial forMtb transmission in
some critical step of the infection cycle in the human host [137]. Al-
though highly speculative, this phenomenon might play a role in TB
cavitation, which is considered to be due to excessive inflammation and
plays a key role in transmitting Mtb bacteria to new susceptible hosts.
Another possibility may be that Mtb has evolved to drive T cell re-
sponses preferentially to highly expressed Mtb epitopes, which would
likely skew reactive T cells from a central memory towards a terminally
exhausted phenotype, as suggested by observations in mice [138],
thereby limiting the formation of a pool of long term memory cells.
Under such a scenario an alternative approach towards vaccine design
would then be to mobilize subdominant epitopes that are less re-
cognized during natural infection, thus not only circumventing the in-
duction of exhaustion but also to broaden the Mtb antigenic repertoire
that can be recognized beyond the natural infection induced repertoire.
A first study to assess the protective efficacy of subdominant Mtb pep-
tides was performed in B6CBAF1 mice using ESAT-6 peptides [139]. It
was demonstrated that Mtb peptides not highly recognized after natural
Mtb infection could induce better protection when used as vaccine
antigens than the naturally immunodominant epitopes. These results
have been subsequently extended to other mouse models (CB6F1;
C57BL/6 and BALB/c) [140,141] and other antigens [142]. Although
the protective efficacy differed among mouse strains, it was shown that
indeed these ESAT-6 subdominant epitopes led to less terminally dif-
ferentiated T cell profiles, with a greater ability to sustain polyfunc-
tional cytokine responses and proliferative capacity over time [141].
Alternative interpretations to the role of hyper conservation of T cell
epitopes, however, exist and hyper conservation could also be due to a
strong evolutionary selection pressure on Mtb protein domains due to
indispensable functions rather than T cell immune pressure. It has been
argued that if T cell recognition was driving epitope conservation, this
should have been restricted mainly to HLA molecules associated with
genetic TB disease susceptibility. However, in clinical Mtb strains iso-
lated from TB endemic areas, Mtb T cell epitopes rarely recognised by
TB patients or restricted to infrequent HLA molecules are not less
conserved than those binding to the most common HLA molecules and
more strongly recognised by TB patients [143].
Recent results have confirmed the low rate of Mtb epitope sequence
variation and found only an small number of variable regions in theMtb
genome [144]. From the encoded sequences of 7 such variable genes
(Rv0001c, RimJ (Rv0995), Rv0012, LldD2 (Rv1872c), Rv0990c,
Rv2719c and TB7.3 (Rv3221c)) (Supplementary Table 1) HLA-I and
HLA-II binding motifs were predicted in silico. Comparative analyses
showed aa changes in predicted CD8+ but not CD4+T cell epitopes.
Interestingly, those substitutions had an effect on the antigenicity of
epitopes in vitro as demonstrated by measuring the INF-γ production
induced in dilute whole blood of 82 TB patients. Hence, variant Mtb
epitopes, generated by aa substitutions, could be either less or more
efficiently recognized than the ancestral peptide. Whether in a vaccine
setting the hypervariable Mtb epitopes would be more efficacious than
conserved Mtb epitopes still needs to be determined. Furthermore, ad-
ditional studies, including other regions such as Asia will be needed to
lend further support for hyperconservation and variation of Mtb epi-
topes.
3.2. Searching novel Mtb antigens
In the prior section, we reviewed different approaches used to
search for novel Mtb peptide epitopes. However, other studies have
used complementary data driven approaches to interrogate the Mtb
genome seeking new Mtb antigens. In several of these approaches ar-
bitrary criteria were used to mine genomic and proteomic databases,
which in one study resulted in the selection of 94Mtb genes predicted to
encode secreted proteins, in particular members of the EsX or PE/PPE
families, expressed in Mtb infected macrophages and up- or down-
regulated in response to hypoxia or carbon starvation [145]. IFN-γ
production in response to these recombinant proteins was tested in
PBMC from PPD− and PPD+ individuals and 48 proteins were found
to be highly reactogenic (Supplementary Table 1). It is interesting to
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note that ten of those antigens were confirmed to contain CD4+ or
CD8+T cell epitopes in subsequent studies (Rv1789, Rv1813c,
Rv1886c, Rv1984c, Rv2220, Rv2608, Rv2875, Rv3020c, Rv3478,
Rv3619c, and Rv3620c) (Fig. 1) [91,102,104,114,129]. The 48 re-
actogenic antigens were then adjuvanted with CpG and each in-
dividually evaluated for protective efficacy in Mtb infected C57BL/6
mice. None of the antigens, although eliciting both antibodies (IgG1
and IgG2) and cytokines (IFN-γ and TNF-α), however, resulted in better
reduction in lung CFU than BCG. Nevertheless, four were selected
(Rv1813c, Rv2608, Rv3619c and Rv3620c) and fused to form the ID93
vaccine, which is now under clinical evaluation in various trials and
trial designs (PoD as well as Prevention of Recurrence (PoR)) in com-
bination with the glucopyranosyl lipid adjuvant (GLA) formulated in SE
[146]. The ID93/GLA-SE fusion protein vaccine [147] was demon-
strated to have similar -though not superior- protective efficacy as BCG
as assessed by CFU in the lungs of Mtb infected mice. It induced pro-
inflammatory cytokines (MCP-1, IL-8, IL-6, IL-5, TNF-α, and GM-CSF)
in cynomolgus macaques and decreased mortality and lung pathology
in guinea pigs, when used in a BCG prime-boost strategy [148].
Additional broad screening of the Mtb antigenome was performed
by using high-throughput proteome microarray technology. In one
study, the screening of 3480 Mtb proteins with pooled TB patients’ sera
reported significant immunoreactivity to 249 proteins; these included
proteins belonging to the PE/PPE, DosR and RD families, as well as
known “conventional” antigens [103]. From these screens, three novel
proteins (Rv1987, Rv3807c, and Rv3887c) were found to be particu-
larly highly reactogenic and to provide better diagnostic sensitivity and
accuracy than commercial serological tests (Supplementary Table 1).
Through a similar approach, the recognition of 4099 Mtb proteins was
tested with sera from 561 TB suspects. This study identified 484 Mtb
proteins that were recognized by the sera of at least one TB patient, and
recognition of 13 proteins was significantly associated with active TB
(Rv3881c, Rv3804c, Rv3874, Rv1860, Rv1411c, Rv2031c, Rv0934,
Rv3616c, Rv3864, Rv1980c, Rv0632c, Rv1984c, and Rv2773) (Sup-
plementary Table 1) [149]. There was no overlap with the proteins
identified in the just mentioned previous study. Although both
screenings identified novel antigens reactive with TB patients’ sera,
current global recommendations from WHO and others do not en-
courage the use of serological tests for TB diagnosis, since the high test
variability leads to high rates of false positive and false negative results
[150].
In another study, which was based on the assumption that CD4+T
cells are required for the maturation of long-lived plasma cells, 164Mtb
proteins that had been identified through serological screening [149],
were interrogated in a search for novel Mtb CD4+T cell antigens
[151]. Polyclonal Mtb-reactive CD4+T cell lines, generated from
PBMC of 12 LTBI (three from USA and nine from India) and two healthy
controls (from USA) exposed to Mtb lysate, were used to test this pro-
teome set. The immunological responses were measured by IFN-γ re-
lease after three days of culturing the T cell lines with irradiated antigen
presenting cells and the respective unpurified antigen. Forty-three
proteins were recognized by CD4+T cells from at least one LTBI or
healthy control, resulting in a total of 27 newly characterized CD4+T
cell Mtb antigens (Supplementary Table 1). Although performed in a
small group of individuals, this study proposed a scalable system that
could be used as a workflow to screen Mtb antigens directly in endemic
areas, and proved that antigens recognized by immunoglobulins often
also react with CD4+T cells.
3.2.1. Integrating Mtb antigen discovery with Mtb infection biology and in
vivo expression in the infected lung
The various approaches described so far have expanded our
knowledge of the Mtb anti genome for T cells and antibodies from LTBI
or TB patients, but did not examine whether and how those antigens
were expressed in the primary TB target organ, the lung. This char-
acteristic might be not essential for TB biomarkers, but it could be
crucial for antigens proposed as potential vaccine candidates. A
minimal prerequisite for a vaccine antigen is that it is expressed by
infected cells in the infected target organ, in this case the lung. Immune
responses directed against Mtb antigens expressed in the lung could
restrain the Mtb immunological life cycle at an early stage and prevent
the onset of TB [152]. Based on this hypothesis, we studied a new class
of Mtb antigens, which we designated IVE-TB (in vivo expressed) anti-
gens [153]. Our first IVE-TB antigen set was based on the analysis of
RNA expression patterns of 2170 Mtb genes in the lung of four mouse
strains at 6 and 9 weeks post-infection. Based on the distinct TB sus-
ceptibility phenotypes of the mouse strains examined (relatively re-
sistant C57BL6 vs. super susceptible C3H/FeJ as polar extremes) Mtb
genes were then selected to represent genes expressed: (i) in-
dependently of host genetic background; (ii) in association with ne-
crosis; (iii) in association with severe necrotic infection or susceptibility
(expressed in the C3H but not B6, C3H.B6-sst1, or B6.C3H-sst1); (iv) in
association with dense granuloma development; (v) in association with
diffuse granuloma development; (vi) in association with resistance; (vii)
in association with low inflammation; (viii) inflammation; and (ix) re-
lapse. This resulted in the first selection of 16 IVE-TB genes, which were
tested as recombinant proteins in vitro and in vivo. IFN-γ responses to
seven IVE-TB antigens were observed in vitro by screening 133
TST+donors (Supplementary Table 1). A further in depth study using
PBMC from six LTBI revealed that the most pronounced T cell subsets
recognizing IVE-TB antigens were IFN-γ+/TNF-α+ CD8+T cells and
TNF-α+/IL-2+ CD154+CD4+T (central memory) cells. Further ex-
periments with one of those IVE-TB antigens, Rv2034, confirmed its in
vivo immunogenicity in HLA-DR transgenic mice by strong induction of
T cells and antibodies [154]. Moreover, immunization with Rv2034 or
the hybrid-protein Ag85B-ESAT6-Rv2034 adjuvanted with CpG or
CAF09 induced over one log reduction in lung CFU compared to un-
vaccinated controls both in Mtb challenged HLA-DR3 transgenic mice
and guinea pigs [154]. Together, these data suggest the potential use of
this novel class of antigens for future TB vaccination.
Building upon these results, we recently selected a second, much
more extensive set of IVE-TB antigens [155]. Data included the relative
gene copy number of 2068Mtb genes expressed in the lungs of the same
B6 vs. C3H mouse strains, but now at multiple different times post-
infection (0-2-4-6-9-12 weeks). A total of 194 genes was found to be
consistently up-regulated independent of the time of infection or the
host genetic background. Bioinformatics was then applied to further
select the most promising genes for functional and immunological
evaluation. These analyses included: (i) the top 15% genes up-regulated
at a late stage of infection; (ii) highly conserved genes with wide HLA
coverage and/or with the highest numbers of predicted HLA class I and
II binders; and (iii) genes with a high homology with M. leprae, the
second human mycobacterial pathogen which is the cause of leprosy. A
total of 50 IVE-TB proteins was selected and analysed, for the first time
using an extensive cytokine screening panel, since IFN-γ is not a cor-
relate of protection in TB. We therefore included also TNF-ɑ, IL-17, IL-
13, IP-10, and GM-CSF. Twenty-nine IVE-TB antigens were strongly
recognized by multi-cytokine production by blood cells from Mtb ex-
posed individuals (n= 12) and LTBI (n= 25) (Supplementary Table 1).
To the best of our knowledge, 17 out of those were described for the
first time as Mtb antigens. Importantly, almost half of the antigens were
recognized by cells producing cytokines other than IFN-γ, including IP-
10 that we recently showed to be mechanistically involved in control-
ling in vitro mycobacterial growth in MGIA assays in recently Mtb in-
fected individuals [156]; and GM-CSF which also has been associated
with protective immunity [157–159]. This data suggest that IFN-γ
based screening approaches may have significantly underestimated as
well biased Mtb antigen discovery studies. These findings are currently
being validated in an independent cohort of LTBI and TB patients and
protection studies are ongoing in different mouse strains to assess the
protective efficacy of the most interesting IVE-TB antigens (personal
communication).
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In both our IVE-TB studies, IVE-TB genes were selected based on the
Mtb transcriptomes conditioned by the interaction between the pa-
thogen and the murine pulmonary (immune) environment. Although
we demonstrated that IVE-TB antigens are strongly recognized by
peripheral cells of LTBI, we could not exclude that the Mtb gene ex-
pression profile in the lung of human hosts might differ from the ones
found in mice. Recently, the analysis of Mtb RNA isolated from the
sputum of untreated TB patients (n= 7) offered the possibility to clo-
sely look at the Mtb transcriptional profile in humans (Supplementary
Table 1) [160]. However, since this study mainly defined up- and down-
regulated genes in RNA isolated from the sputum of TB patients to RNA
isolated from in vitro culturedMtb H37Rv, a direct comparison with our
findings is not possible at this stage. Nevertheless, since the necrotic
phenotype of TB lesions in the C3H model closely resembles key fea-
tures of human TB lesions (caseating necrotic granulomas accompanied
by hyper-susceptibility), as discussed by Kramnik et al. [161] pre-
viously, we contend our model is an important novel tool in the dis-
covery of highly expressed antigens in affected target organs, not only
for TB but also other diseases were similar approaches can be adopted.
4. Summary and implications
The discovery of Mtb antigens that correlate with infection, pro-
tection and vaccine immunogenicity is a complex process that has
evolved over decades, and now is yielding important new results. The
first goal is to identify the proteins and peptides that are expressed by
the pathogen and can be recognized by the host immune system. In the
early stages of antigen discovery, there were significant limitations in
the resolution of biochemical technologies used to isolate and char-
acterize proteins from Mtb from in vitro cultures. These limitations were
overcome first by the availability of Mtb genome wide expressing li-
braries and subsequently by the availability of the whole Mtb genome
sequence. This allowed informational and experimental access to the
entire Mtb antigenome, with its approximately 4000 ORFs. These have
been probed now extensively for their potential antigenicity, using
several genome wide strategies. This has led to the identification of
3282 Mtb (ID1773) epitopes and more than 500 Mtb antigens (IEDB,
www.iedb.org, March 2017). However, as described in the past [113],
the majority of the Mtb epitopes included in IEDB disproportionally
(54%) belongs to a relatively small proportion of proteins (n= 26).
The novel approaches discussed in this review have typically de-
fined the antigenicity of recombinant peptides and proteins by in vitro
measuring of IFN-γ and proliferative T cell responses using PBMC, T cell
lines or whole blood from LTBI donors. We contend that additional
parameters need to be included as well, based in part on our own ob-
servations that many new Mtb antigens were recognized by cells pro-
ducing cytokines other than IFN-γ, and often no IFN-γ at all [155]. This
suggests that IFN-γ based screening approaches may not have captured
the Mtb antigenome adequately. This also is evident when examining
alternative T cell responses such as those restricted by HLA-E, which
often release Th2 rather than Th1 cytokines [130].
Current diagnostic tests, including TST and IGRA, have poor prog-
nostic capacity in predicting which Mtb infected individuals will pro-
gress towards TB, that would allow rapid preventive treatment of these
subjects to decrease the risk of Mtb transmission. Differences in Mtb
antigen specific IFN-γ production and in polyfunctionality of T cell
responses, such as to Rpf or DosR regulon antigens, have been found
repeatedly between LTBI and TB patients [28,162]. However, not many
of such antigens have been assessed in longitudinal follow-up studies of
TB household contacts to examine whether they could predict TB pro-
gression. The novel epitopes or antigens identified by wide genome
screenings as discussed above have been evaluated sporadically in
multiple TB cohorts. When analysed, very few differences in the mag-
nitude and frequency of responses, which were mostly IFN-γ centred,
were found between TB patients and LTBI [102,114,124,131,153].
However, the number of subjects included in those studies was
generally quite low and future studies would need to screen larger
cohorts including follow-up analyses to capture their disease -or pro-
tection- association. Such studies could also be interesting as they might
elucidate how the immune response repertoire against antigens/epi-
topes is shaped during the natural course of infection. That is important
considering that antigens highly expressed at early stage of infection
can lead to T cell exhaustion and dysfunction [163,164] while others
not evoking exhaustion could induce long term memory. Moreover,
most of the novel Mtb antigens/epitopes identified have high homo-
logies to antigens from NTM or other bacteria [124,125], including
those present in human microbiota. How this impacts their re-
actogenicity in TB needs to be clarified. Additionally, the currently used
rather narrowly focused immunological read-outs (mostly IFN-γ or
polyfunctional CD4+T cell centred) are unlikely to detect im-
munological changes in other domains of immunity, which widely
occur in Mtb carrying hosts as they transit from a stage of controlling
Mtb infection to a process culminating in active TB disease [165–167].
Identifying such changes and defining the corresponding biomarkers of
TB risk would greatly facilitate early TB diagnosis and prediction of TB
onset at an early stage. Innovative animal models, like cynomolgus
macaques that can display the entire human TB clinical spectrum
[168,169], and which can also recognize CD4+ epitope pools defined
in humans [170] would be of great value to help identifying such
markers in translational studies.
As evident from the above, most Mtb genome wide antigen dis-
coveries have relied on samples from LTBI donors. Those individuals
are interesting from a vaccine development point of view, since LTBI
results in an almost 80% lower risk of developing active TB than non-
LTBI subjects upon re-infection [171]. However, the underlying biolo-
gical mechanisms and immune correlates remain unknown. Most stu-
dies today still follow IFN-γ oriented approaches although we know that
the presence of activated [172] and polyfunctional (IFN-γ+/IL-2+/
TNF-α+) T cells are not correlates or sufficient mediators of protection
[57,143]. A recent study in mice demonstrated that CD4+T cells ac-
tivated by systemic peptides administration was able to reach the lung
parenchyma but, critically, failed to act directly with Mtb infected cells
[173].Mtb infected cells have the ability to decoy immune cells through
different mechanisms such as suboptimal antigen presentation, ex-
porting antigens to bystander uninfected cells reducing the recognition
of those cells containing the mycobacteria, the release of inhibitory
cytokines or the induction of inhibitory mechanisms such as regulatory
T cells [9,174–176]. It would be interesting to study whether the decoy
activity is restricted to certain antigens, such as secreted Mtb antigens.
If so, vaccine strategies might need to be focused on non-secreted an-
tigens, which would be contrary to most current thinking.
To advance novel antigens into the TB vaccine pipeline it will be
necessary to prove their immunogenicity and especially their protective
efficacy in preclinical animal models of increasing complexity and re-
levance to human TB. To our knowledge, from all antigens identified by
recent genome wide strategies, only few antigens (http://www.tbvi.eu/
what-we-do/pipeline-of-vaccines/) have been tested in vivo. Mice are
generally used as first line in vivo model and usually the protective ef-
fects of adjuvanted/vectored proteins are tested alone and compared to
BCG. This might not be the best strategy since most protein based
subunit vaccine candidates aim to boost BCG vaccination, and there
could be antigens able to improve the protective efficacy of BCG but not
as much reduce the bacterial load as stand-alone vaccines. Moreover,
the diversity in mouse strains, regimens, adjuvants, infection challenges
and doses used differ widely and impede a comparison between dif-
ferent vaccine candidates. In that regard, a head-to-head comparison of
vaccine candidates in the same models and experiments should be
strongly promoted to provide more solid and consistent data in the pre-
clinical stage of vaccine development. TBVI is one of the first organi-
sations that has been promoting such a TB vaccine selection process
during the past decade [177].
In conclusion, genome wide strategies have discovered a wealth of
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new Mtb antigens and epitopes that have escaped detection by previous
classical methodologies, with interesting overlaps among those identi-
fied by independent approaches (Supplementary Table 1) (Fig. 1).
Unlocking their potential as vaccine targets as well as TB biomarker
antigens, e.g. for diagnostic or prognostic purposes, will be the next
fascinating challenge.
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